The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture

Antiviral Research

Volumn 39, Issue 1, 1998, Pages 35-46

  Lawetz, Carol ^a   Liuzzi, Michel ^a  

^a Boehringer Ingelheim   (Canada)

Author keywords

Antiviral; ELISA; Herpes simplex; Ribonucleotide reductase; Synergy

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; BILD 1351 SE; ENZYME INHIBITOR; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL STRAIN BHK; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HERPES SIMPLEX VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HERPESVIRUS 1, HUMAN; RIBONUCLEOTIDE REDUCTASES; VERO CELLS;

ANIMALIA; CRICETINAE; HERPES; HUMAN HERPESVIRUS 1;

EID: 0032128569     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00028-X     Document Type: Article

References (25)

1. Brazeau P., Ling N., Bohlen P., Esch F., Ying S.Y., Guillemin R. Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vivo. Proc. Natl. Acad. Sci. 79:1982;7909-7913.
2. Chou J.H. Quantitation of synergism and antagonism of two or more drugs by computerized analysis. Chou T.C., Rideout D.C. Synergism and Antagonism in Chemotherapy. 1991;223-241 Academic Press, New York.
3. Chou T.C. The median effect principle and the combination index for quantitation of synergism and antagonism. Chou T.C., Rideout D.C. Synergism and Antagonism in Chemotherapy, 1991;61-102 Academic Press, New York.
4. Cohen E.A., Gaureau P., Brazeau P., Langelier Y. Specific inhibition of herpesvirus ribonucleotide reductase by a nonapetide derived from the carboxy terminus of subunit 2. Nature. 321:1986;441-443.
5. Cosentino G., Lavallée P., Rhakit S. et al. Specific inhibition of ribonucleotide reductases by peptides corresponding to the C-terminal of their second subunit. Nature. 69:1991;79-83.
6. Daikoku T., Yamamoto N., Maeno K., Nishiyama Y. Role of viral ribonucleotide reductase in the increase of dTTP pool size in herpes simplex virus-infected vero cells. J. Gen. Virol. 72:1991;1441-1444.
7. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods. 89:1986;271-277.
8. Dutia B.M., Frame M.C., Subak-Sharpe J.H., Clark W.N., Marsden H.S. Specific inhibition of herpesvirus ribonucleotide reductase by synthetic peptides. Nature.321:1986;439-443.
9. Erikson S., Sjöberg B.M. Ribonucleotide reductase. Hervé G. Allosteric Enzymes. 1989;189-215 CRC Press, Boca Raton.
10. Furman P.A., Lambe C.U., Nelson D.J. Effect of acyclovir on the deoxyribonucleoside triphosphate pool levels in vero cells infected with HSV-1. Am. J. Med. 73:1982;14-17.
11. Goldstein D.J., Weller S.K. Factor(s) present in herpes simplex virus type-1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: charaterization of an ICP6 deletion mutant. Virology. 166:1988;41-51.
12. Honess R.W., Roizman B. Proteins specified by herpes simplex virus XI. Identification and relative molar rates of synthesis of structural and nonstructural herpes virus polypeptides in the infected cell. J. Virol. 12:1973;1347-1365.
13. Jamieson A.T., Bjursell G. Deoxyribonucleoside triphosphate pools in herpes simplex type-1 infected cells. J. Gen. Virol. 31:1976;101-113.
14. Liuzzi M., Déziel R., Moss N. et al. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature. 372:1994;695-698.
15. Moss N., Beaulieu P., Duceppe J.S. et al. Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity. J. Med. Chem. 39:1996;4173-4180.
16. O'Brien J.J., Campoli-Richards D.M. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 37:1989;233-309.
17. Prichard M.N., Shipman C. Jr. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:1990;181-206.
18. Prichard M.N., Shipman C. Jr. Ribonucleotide reductase: An important enzyme in the replication of herpes simplex virus type-1 and a target for antiviral chemotherapy. Chemotherapy. 41:1995;384-395.
19. Reardon J.E., Spector T. Acyclovir: mechanism of action and potentiation by ribonucleotide reductase inhibitors. August T. Advances in Pharmacology. 1991;1-27 Academic Press, New York.
20. Roizman B., Sears A.E. Herpes simplex viruses and their replication. Roizman B., Whitley R.J., Lopez C. The Human Herpesviruses, 1993;11-68 Raven Press, New York.
21. Spector T. 348U87: an inactivator of herpes virus ribonucleotide reductase that potentiates the antiviral activity of acyclovir. Drugs Future. 18:1993;25-28.
22. Spector T., Harrington J.A., Morrison R.W. Jr., Lambe C.U., Nelson D.J., Averett D.R., Biron K., Furman P.A. 2-Acetyl-pyridine 5-[(dimethylamino)thiocarbonyl] thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella zoster viruses and a potentiator of acyclovir. Proc. Natl. Acad. Sci. 86:1989;1051-1055.
23. Suhnel J. Evaluation of synergism or antagonism for the combined action of antiviral agents. Antivir. Res. 13:1990;23-40.
24. Takeuchi H., Baba M., Shigeta S. An application of tetrazolium (MTT) colorimetric assay for the screening of anti-herpes simplex virus compounds. J. Virol. Methods. 33:1991;61-71.
25. Trybala E., Bergstrom T., Svennerholm B., Jeansson S., Glorioso J.C., Olofsson S. Localization of a functional site on herpes simplex virus type-1 glycoprotein C involved in binding to cell surface heparan sulphate. J. Gen. Virol. 75:1994;743-752.